Researchers at the University of Southern California identified a hidden trigger for Alzheimer’s disease and potential drug compounds to inhibit it [1, 2].
The discovery targets the mechanism of brain inflammation and the formation of amyloid plaques. This is particularly significant for individuals who carry the high-risk APOE4 gene, as these biological markers are central to the progression of the disease [1, 2].
The research team said that inhibiting a specific enzyme can reduce the harmful inflammation that characterizes the condition [1, 2]. While reports from the university differ on the specific identity of the enzyme, with one citing cPLA2 and another citing a newly identified enzyme called IDOL, both findings suggest that blocking the enzyme's activity may limit plaque buildup [1, 2].
This process involves the use of drug compounds designed to shut down the enzyme's trigger mechanism. By preventing the enzyme from fueling inflammation, the researchers aim to slow or stop the neurodegenerative damage associated with Alzheimer's [1, 2].
The study was conducted at the University of Southern California in Los Angeles, California [1, 2]. The findings were reported on May 25, 2026 [1, 2].
Scientists are now focusing on how these compounds can be refined into viable treatments. The goal is to create a therapeutic pathway that specifically targets the inflammatory response without disrupting other essential brain functions [1, 2].
“Researchers at the University of Southern California identified a hidden trigger for Alzheimer’s disease.”
The identification of a specific enzymatic trigger provides a concrete molecular target for drug development. If these compounds can successfully reduce amyloid plaques and inflammation in humans, it could shift Alzheimer's treatment from managing symptoms to modifying the disease's progression, especially for those with the APOE4 genetic predisposition.
